MUMBAI / NEW DELHI, SEPTEMBER 25, 2026 — During trading on Friday, September 25, 2026, lab-grown diamond manufacturer Anjali LabTech Ltd officially re-submitted its updated draft red herring prospectus (DRHP) to the Securities and Exchange Board of India (SEBI) for an initial public offering targeting ₹1,225 crore, according to regulatory filings reported by The Economic Times.
The proposed public issue comprises a fresh capital raising of ₹925 crore alongside an Offer For Sale (OFS) component by existing promoter shareholders. Furthermore, corporate disclosures indicate that Anjali LabTech is exploring a pre-IPO placement round to aggregate up to ₹185 crore prior to the finalization of the red herring prospectus. Net proceeds from the fresh issue are earmarked toward funding capital expenditure requirements for manufacturing expansion and general corporate purposes.
Key Issue Details & Financial Parameters
| Parameter / Metric | Details |
|---|---|
| Total Issue Size | ₹1,225 Crore |
| Fresh Issue Component | ₹925 Crore |
| Offer For Sale (OFS) | Promoter-led selling stake |
| Pre-IPO Placement Target | Up to ₹185 Crore |
| Price Band & Lot Size | Pending RHP filing |
| Listing Exchanges | BSE & NSE India |
Key Dates & Timeline Calendar
| Event / Catalyst Milestone | Exact Calendar Date |
|---|---|
| DRHP Re-filing Submission | September 25, 2026 |
| SEBI Observations & Approval | Pending official confirmation |
| Bidding Window (Open / Close) | Pending RHP filing |
| Basis of Allotment | Pending RHP filing |
| Listing Date (BSE & NSE) | Pending RHP filing |
Grey Market Premium (GMP) Tracking Status
As Anjali LabTech has only just re-submitted its updated draft papers to SEBI on September 25, 2026, the public issue is in the preliminary regulatory clearance phase. GMP data is pending initial price discovery across primary tracking platforms (Chittorgarh & IPOWatch). Institutional analysts and retail investors should monitor forthcoming announcements regarding price band finalization.
In-Depth Analysis: The Lab-Grown Diamond Sector Opportunity
According to market research compiled by sector analysts, the Indian lab-grown diamond (LGD) manufacturing segment is witnessing accelerated adoption due to shifting consumer preferences toward sustainable, eco-friendly luxury goods and cost-efficient alternatives to mined diamonds. Filings submitted to BSE and NSE India confirm that capital allocation from the ₹925 crore fresh issue will strengthen technological infrastructure.
Capital Deployment & Pre-IPO Strategy
Brokerage notes highlight that the planned pre-IPO placement of up to ₹185 crore will assist in moderating overall dilution for existing shareholders prior to public price discovery. Fundamental metrics from financial databases like Screener.in and Trendlyne will provide granular insights into return on capital employed (ROCE) and EBITDA margins once the updated financial statements are formally unlocked in the final RHP.
Peer Comparison Context
| Company / Peer Name | P/E Ratio | Market Cap / Issue Size | Key Note |
|---|---|---|---|
| Anjali LabTech Ltd (Proposed) | Pending | ₹1,225 Cr Issue | Fresh issue & promoter OFS |
| Sector Peers (LGD Segment) | Pending | Various | Peer comparison data pending verification |
Peer valuation data sourced from Screener.in and Trendlyne
Investor Framework: Bull vs. Bear Catalysts
Growth Catalysts (Bull Case)
- Secular Industry Tailwinds: Rapid global and domestic escalation in lab-grown diamond jewellery demand.
- Balance Sheet Strengthening: Fresh issue proceeds of ₹925 crore directly improve internal liquidity and fund capital expenditure.
- Strategic Pre-IPO Funding: Potential ₹185 crore pre-IPO placement validates institutional interest.
Key Downside Risks (Bear Case)
- Pricing Volatility: Fluctuations in international rough and polished lab-grown diamond realisations.
- Promoter Selling: Presence of an OFS component means partial promoter dilution upon listing.
Investment Verdict
Suitable For: Institutional and high-risk equity investors tracking manufacturing themes
Risk Level: High — rapid pricing adjustments in global LGD markets warrant cautious evaluation
Key Watch Point: Final price band determination and financial margin health disclosed in the RHP
Frequently Asked Questions
Should investors apply for Anjali LabTech IPO shares based on valuations?
Valuation metrics and price bands are currently pending formal RHP disclosure following the September 25, 2026 SEBI re-filing. Investors should evaluate financial multiples against sector peers once pricing details are published.
What is the Grey Market Premium (GMP) and expected listing sentiment for Anjali LabTech?
GMP data is pending initial price discovery across primary tracking platforms (Chittorgarh & IPOWatch) as the IPO is in early regulatory filing stages.
What are the primary balance sheet strengths and risk factors for Anjali LabTech?
The primary balance sheet catalyst is the infusion of ₹925 crore in fresh capital expenditure funds, while key risks involve commodity price fluctuations in the lab-grown diamond sector.
SEBI Compliance & Statutory Disclaimer
The information and analysis presented on IPO Bulletin (ipobulletin.com) are for informational and educational purposes only and do not constitute financial, investment, or legal advice. Securities market investments are subject to market risks; please read all offer documents (DRHP/RHP) thoroughly before committing capital. Grey Market Premium (GMP) figures are unofficial, unregulated street estimates. Always consult a SEBI-registered investment advisor before making financial decisions.
Sources cross-checked for this article: Chittorgarh, Moneycontrol, The Economic Times Markets Feed, BSE India filings, Screener.in